par Millot, Frédéric;Suciu, Stefan 
;Philippe, N;Benoît, Yves;Mazingue, F;Uyttebroeck, Anne;Lutz, Pierre;Mechinaud, F;Robert, Alain;Boutard, Patrick;Marguerite, Geneviève;Ferster, Alina ;Plouvier, Emmanuel;Rialland, X;Behard, C;Plantaz, D;Dresse, Marie-Françoise;Philippet, Pierre;Norton, Lucilia;Thyss, Antoine;Dastugue, Nicole;Waterkeyn, C;Vilmer, E;Otten, Jacques ;Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer,
Référence Journal of clinical oncology, 19, 7, page (1935-1942)
Publication Publié, 2001-04
;Philippe, N;Benoît, Yves;Mazingue, F;Uyttebroeck, Anne;Lutz, Pierre;Mechinaud, F;Robert, Alain;Boutard, Patrick;Marguerite, Geneviève;Ferster, Alina ;Plouvier, Emmanuel;Rialland, X;Behard, C;Plantaz, D;Dresse, Marie-Françoise;Philippet, Pierre;Norton, Lucilia;Thyss, Antoine;Dastugue, Nicole;Waterkeyn, C;Vilmer, E;Otten, Jacques ;Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer, Référence Journal of clinical oncology, 19, 7, page (1935-1942)
Publication Publié, 2001-04
Article révisé par les pairs
| Résumé : | The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen. |
